

MEMORANDUM

Date: December 18, 2000

From: Therapy for Treatment-Experienced Patients Working Group
Division of Antiviral Drug Products

Through: Heidi Jolson, M.D., M.P.H.
Director, Division of Antiviral Drug Products

Subject: General Meeting Plan for January 11, 2001 Advisory
Committee

Please refer to the December 4, 2000 background package. Under the "General Meeting Plan" section it was suggested that members of the Advisory Committee and guests consider preparing original trial design approaches for discussion at the meeting. There will be an opportunity to describe your trial design options during the morning "Questions to the Committee" session. These will be discussed with question 2, "Please comment on the strengths and weaknesses of the trial design options presented." Please feel free to put your ideas on overheads, however we ask that you confine your comments to one overhead if possible. If you have any additional questions, please contact Kimberly Struble, Pharm.D., at 301-827-2330.